Skip to main content

Value of Echocardiographic Right Ventricular and Pulmonary Pressure Assessment in Predicting Transcatheter Tricuspid Repair Outcome.

JACC. Cardiovascular interventions

Authors: Nicole Karam, Michael Mehr, Maurizio Taramasso, Christian Besler, Tobias Ruf, Kim A Connelly, Marcel Weber, Ermela Yzeiraj, Davide Schiavi, Antonio Mangieri, Laura Vaskelyte, Hannes Alessandrini, Florian Deuschl, Nicolas Brugger, Hasan Ahmad, Edwin Ho, Luigi Biasco, Mathias Orban, Simon Deseive, Daniel Braun, Mara Gavazzoni, Karl-Philipp Rommel, Alberto Pozzoli, Christian Frerker, Michael Näbauer, Steffen Massberg, Giovanni Pedrazzini, Gilbert H L Tang, Stephan Windecker, Ulrich Schäfer, Karl-Heinz Kuck, Horst Sievert, Paolo Denti, Azeem Latib, Joachim Schofer, Georg Nickenig, Neil Fam, Stephan von Bardeleben, Philipp Lurz, Francesco Maisano, Jörg Hausleiter

OBJECTIVES: The aim of this study was to assess the value of echocardiographic right ventricular (RV) and systolic pulmonary artery pressure (sPAP) assessment in predicting transcatheter tricuspid edge-to-edge valve repair (TTVR) outcome.

BACKGROUND: RV dysfunction and pulmonary hypertension are associated with poor prognosis and are systematically sought during tricuspid regurgitation evaluation. The value of echocardiographic assessment in predicting TTVR outcome is unknown.

METHODS: Data were taken from the TriValve (Transcatheter Tricuspid Valve Therapies) registry, which includes patients undergoing TTVR at 14 European and North American centers. The primary outcome was 1-year survival free from hospitalization for heart failure, and secondary outcomes were 1-year survival and absence of hospital admission for heart failure at 1 year.

RESULTS: Overall, 249 patients underwent TTVR between June 2015 and 2018 (mean tricuspid annular plane systolic excursion [TAPSE] 15.8 ± 15.3 mm, mean sPAP 43.6 ± 16.0 mm Hg). Tricuspid regurgitation grade ≥3+ was found in 96.8% of patients at baseline and 29.4% at final follow-up; 95.6% were in New York Heart Association functional class III or IV initially, compared with 34.3% at follow-up (p < 0.05). Final New York Heart Association functional class did not differ among TAPSE and sPAP quartiles, even when both low TAPSE and high sPAP were present. Rates of 1-year survival and survival free from hospitalization for heart failure were 83.9% and 78.7%, respectively, without significant differences according to baseline echocardiographic RV characteristics (TAPSE, fractional area change, and end-diastolic area) and sPAP (p > 0.05 for all).

CONCLUSIONS: TTVR provides clinical improvement, with 1-year survival free from hospital readmission >75% in patients with severe tricuspid regurgitation. Conventional echocardiographic parameters used to assess RV function and sPAP did not predict clinical outcome after TTVR.

Copyright © 2020 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

PMID: 32360260

Participating cluster members